Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 105Neoplasm Metastasis 6Neoplasms 4Breast Diseases 4Ovarian Neoplasms 3Neoplasms by Site 3Hereditary Sensory and Autonomic Neuropathies 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms, Male 3Triple Negative Breast Neoplasms 2Multiple Endocrine Neoplasia Type 1 2Endometrial Neoplasms 2Breast Cancer Metastatic 2Anatomic Stage II Breast Cancer AJCC v8 2Advanced Breast Cancer 2Venous Thromboembolism 1Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Osteitis Deformans 1Neoplastic Cells, Circulating 1Mesothelioma 1Lymphoma 1Lung Neoplasms 1Locoregional Recurrence 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Leukemia 1Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer 1Hematologic Neoplasms 1

Interventions

ribociclib 1Pharmacogenomic Variants 1Aromatase Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Estrogen Receptor and/or Progesterone Receptor Positive × ribociclib × Breast × Clear all
NCT03477396 2024-02-20

Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer

City of Hope Medical Center

Phase 2 Completed
2 enrolled 13 charts
Breast

Estrogen Receptor and/or Progesterone Receptor Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡